These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 675374)

  • 21. Global and effective synergism of amikacin, gentamicin or tobramycin when combined with carbenicillin against Pseudomonas aeruginosa.
    Ximenes J; Hirai CK; Takenaka IM
    J Int Med Res; 1979; 7(5):375-8. PubMed ID: 115732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired cross resistance to aminoglycosides in gentamicin-sensitive and gentamicin-resistant strains of enterobacteria.
    Al-Asadi MJ; Towner K; Greenwood D
    J Med Microbiol; 1981 May; 14(2):171-83. PubMed ID: 7014903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro activity of netilmicin, amikacin, tobramycin and sisomicin against gentamicin highly-resistant enterobacteriaceae.
    Tselentis J; Legakis NJ; Nicolas KJ; Melissinos K; Papavassiliou J
    Chemotherapy; 1980; 26(6):409-17. PubMed ID: 7408554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns.
    Acar JF; Witchitz JL; Goldstein F; Talbot JN; Le Goffic F
    J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.
    Murray PR
    Antimicrob Agents Chemother; 1980 Mar; 17(3):474-6. PubMed ID: 6252830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gentamicin-resistant Serratia marcescens endophthalmitis.
    Gammon JA; Schwab I; Joseph P
    Arch Ophthalmol; 1980 Jul; 98(7):1221-3. PubMed ID: 6994702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.
    Gerding DN; Larson TA
    Am J Med; 1985 Jul; 79(1A):1-7. PubMed ID: 4025364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of amikacin and ten other aminoglycoside antibiotics against gentamicin-resistant bacterial strains.
    Reyonolds AV; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S291-6. PubMed ID: 62815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical pharmacology of the most frequently used aminoglucosides: gentamycin, tobramycin and amikacin].
    Cuena Boy R; Azanza Perea JR; Echeverría Echepare LM; Honorato Pérez J
    Rev Med Univ Navarra; 1983 Dec; 27(4):21-7. PubMed ID: 6676898
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro activity of netilmicin compared with gentamicin, tobramycin, amikacin, and kanamycin.
    Eickhoff TC; Ehret JM
    Antimicrob Agents Chemother; 1977 May; 11(5):791-6. PubMed ID: 879733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sensitivity of 1041 strains of bacteria obtained from an intensive care unit with regard to aminoglycosides].
    Beney E; Robert D; Tigaud S; Blanc PL; Vincent P
    Nouv Presse Med; 1982 Nov; 11(46):3396-9. PubMed ID: 7155847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence in a burn center of populations of bacteria resistant to gentamicin, tobramycin, and amikacin: evidence for the need for changes in zone diameter interpretative standards.
    Minshew BH; Pollock HM; Schoenknecht FD; Sherris JC
    Antimicrob Agents Chemother; 1977 Dec; 12(6):688-96. PubMed ID: 412464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Enterobacteria isolated in hospitals. Comparison of the bacteriostatic and bactericidal activity of amikacin, gentamicin and tobramycin].
    Kazmierczak A; Gailliard MC; Pothier P; Siebor E; Portier H
    Nouv Presse Med; 1979 Oct; 8(42):3399-402. PubMed ID: 537884
    [No Abstract]   [Full Text] [Related]  

  • 37. [Studies on the antimicrobial activities of gentamicin, amikacin, and tobramycin against Pseudomonas aeruginosa isolated at Hokkaido University Hospital].
    Sato K; Matsumiya H; Saito A
    Jpn J Antibiot; 1982 May; 35(5):1240-8. PubMed ID: 6813532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity, synergism, and testing parameters of amikacin, with comparisons to other aminoglycoside antibiotics.
    Kelly MT; Matsen JM
    Antimicrob Agents Chemother; 1976 Mar; 9(3):440-7. PubMed ID: 1259402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Distribution of aminoside resistance in 430 strains of gram-negative bacilli in a hospital environment. Value of amikacine].
    Le Noc P; Croizé J
    Sem Hop Ther; 1977; 53(7-8):378-83. PubMed ID: 244369
    [No Abstract]   [Full Text] [Related]  

  • 40. Changes in resistance to aminoglycoside antibiotics of different bacterial strains isolated during the period 1978 to 1983. Netilmicin as alternative therapy.
    Bovelacci A; Montini G; Ramacciotti PG
    Chemioterapia; 1985 Dec; 4(6):439-44. PubMed ID: 3830413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.